On the other hand, if it is a patient with extreme hypertriglyceridemia, who is at riskforpancreatitis, for example, then the fibrate would be theagent that would bemoreimportant.
Recently we have seen additional examples of favorable changes in laboratory tests without the expected reduction in risk for tight glucose control for diabetes, fibrate therapy for diabetics, and niacin therapy for patients with heart disease.